| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 2.0 | 0.0 |
| Profit before tax | -38.7 | -35.3 |
| Net income | -38.7 | -35.3 |
| EPS (diluted, $ a share) | $-2.46 | $-2.28 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: INBX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Inhibrx Biosciences, Inc.: key numbers
- Share price
- $74.18Close, Nov 17
- Market cap
- $1.1B
- Shares outstanding
- 14.77MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Inhibrx Biosciences, Inc.
All →Inhibrx Biosciences Financial Results
Inhibrx Biosciences reported Q3 2026 financial results, highlighting a cash position of $199.5 million and $2.0 million in revenue from a licensing agreement with Pfizer. The company is advancing its clinical pipeline, with upcoming data presentations for ozekibart in Ewing sarcoma and ongoing enrollment in the Phase 2 HexAgon study for ordastobart.
- Term
- Q3 2026
Inhibrx Biosciences CEO Mark Lappe Buys $832K of Stock
Mark Lappe, CEO, bought 9,840 shares of Inhibrx Biosciences, Inc. at $84.07 to $85.00 a share (average $84.54) in 4 transactions, worth $832K in total on Oct 14, 2026. Shares held after the trade: 169,900 (+1.5%).
- Value
- $832K
- Shares
- 9,840
- Average price
- $84.54
- Role
- CEO
- Holding change
- +1.5%
- Trade date
- Oct 14, 2026
Inhibrx Biosciences Investor Presentation
Inhibrx Biosciences, Inc. has updated its corporate investor presentation, which is being used for meetings and conferences with the investment community. The presentation provides a summary of the company's business strategy and clinical pipeline updates for its investigational product candidates.